Display options
Cite
Jia JY, Lu YL, Li XC, et al. Pharmacokinetics of depside salts from Salvia miltiorrhiza in healthy Chinese volunteers: A randomized, open-label, single-dose study. Curr Ther Res Clin Exp. 2010;71(4):260-71doi: 10.1016/j.curtheres.2010.08.004.
Jia, J. Y., Lu, Y. L., Li, X. C., Liu, G. Y., Li, S. J., Liu, Y., Liu, Y. M., Yu, C., & Wang, Y. P. (2010). Pharmacokinetics of depside salts from Salvia miltiorrhiza in healthy Chinese volunteers: A randomized, open-label, single-dose study. Current therapeutic research, clinical and experimental, 71(4), 260-71. https://doi.org/10.1016/j.curtheres.2010.08.004
Jia, Jing-Ying, et al. "Pharmacokinetics of depside salts from Salvia miltiorrhiza in healthy Chinese volunteers: A randomized, open-label, single-dose study." Current therapeutic research, clinical and experimental vol. 71,4 (2010): 260-71. doi: https://doi.org/10.1016/j.curtheres.2010.08.004
Jia JY, Lu YL, Li XC, Liu GY, Li SJ, Liu Y, Liu YM, Yu C, Wang YP. Pharmacokinetics of depside salts from Salvia miltiorrhiza in healthy Chinese volunteers: A randomized, open-label, single-dose study. Curr Ther Res Clin Exp. 2010 Aug;71(4):260-71. doi: 10.1016/j.curtheres.2010.08.004. PMID: 24688148; PMCID: PMC3969617.
Copy Download .nbib Format: NLM
Share it on

Curr Ther Res Clin Exp. 2010 Aug;71(4):260-71. doi: 10.1016/j.curtheres.2010.08.004.

Pharmacokinetics of depside salts from Salvia miltiorrhiza in healthy Chinese volunteers: A randomized, open-label, single-dose study.

Current therapeutic research, clinical and experimental

Jing-Ying Jia, You-Li Lu, Xiao-Chuan Li, Gang-Yi Liu, Shui-Jun Li, Yun Liu, Yan-Mei Liu, Chen Yu, Yi-Ping Wang

Affiliations

  1. Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, China.
  2. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  3. Central Laboratory, Shanghai Xuhui Central Hospital, Shanghai, China ; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

PMID: 24688148 PMCID: PMC3969617 DOI: 10.1016/j.curtheres.2010.08.004

Abstract

BACKGROUND: Depside salts from Salvia miltiorrhiza, with active components of lithospermic acid B (LSB), rosmarinic acid (RA), and lithospermic acid (LA), are a multicomponent drug marketed in China for the treatment of coronary heart disease.

OBJECTIVES: The aims of this study were to determine the concentrations of LSB, RA, and LA in human plasma and urine, and to compare the pharmacokinetic properties of depside salts from S miltiorrhiza in healthy Chinese volunteers.

METHODS: A randomized, open-label, single-dose study was conducted in healthy Chinese volunteers. Participants were randomly assigned to receive a single intravenous infusion of 100 or 200 mg of depside salts from S miltiorrhiza. Blood was collected through a venous cannula prior to study drug administration (0 min) and at 10, 20, 30, 60, 65, 70, 80, and 90 minutes and 2, 3, 4, 6, 8, 12, and 24 hours after study drug administration. Urine samples were taken before study drug administration (0) and at 0 to 12 and 12 to 24 hours after study drug administration. LSB, RA, and LA concentrations in serum and urine were analyzed by an LC-MS/MS method. Tolerability was determined by clinical assessment; vital signs (ie, blood pressure, heart rate, breathing rate, body temperature) monitoring at baseline and at the end of the study, clinical laboratory tests (ie, hematology, blood biochemistry, hepatic function, renal function, urinalysis), 12-lead ECG measurements, and physical examinations at baseline and after completion of the study.

RESULTS: Twelve Chinese volunteers (6 males, 6 females; mean [SD] age, 25.2 [3.8] years; mean height, 165.7 [8.9] cm; mean body mass index, 21.6 [2.5] kg/m(2)) were enrolled in the study. Peak plasma concentrations of LSB, RA and LA were observed at 0.3 to 1 hour following the 1-hour intravenous infusion, with respective mean (SD) Cmax of 4925 (1861), 174 (61), and 361 (101) ng/mL for the 100-mg dose and 10,285 (2259), 308 (77), and 674 (85) ng/mL for the 200-mg dose. The AUClast values for LSB, RA, and LA were 4537 (1265), 129 (28), and 1229 (330) ng/mL/h, respectively, for the 100-mg dose and 10,426 (2589), 260 (53), and 2792 (729) ng/mL/h for the 200-mg dose. No significant difference in pharmacokinetic parameters was observed between male and female subjects. Three metabolites were found in the plasma with low concentrations. The urinary excretion recoveries of LSB, RA, and LA were 0.58% (0.42%), 25.21% (20.61%), and 10.02% (7.72%) for the 100-mg dose and 0.38% (0.18%), 20.11% (10.50%), and 6.34% (3.20%) for the 200-mg dose. No adverse events were reported by the subjects or found by the investigators in the analysis of vital signs, 12-lead ECG measurements, physical examinations, or clinical laboratory tests.

CONCLUSIONS: Following single intravenous infusion of 100 or 200 mg of depside salts from S miltiorrhiza to healthy Chinese subjects, no statistical differences in pharmacokinetic parameters were observed between males and females. The 2 doses of depside salts from S miltiorrhiza were clinically well tolerated during the study.

Keywords: LC-MS/MS; healthy volunteers; liquid chromatography tandem mass spectrometry; lithospermic acid; lithospermic acid B; pharmacokinetics; rosmarinic acid

References

  1. Drug Metab Dispos. 2007 Feb;35(2):234-9 - PubMed
  2. Planta Med. 2001 Jun;67(4):366-8 - PubMed
  3. Acta Pharmacol Sin. 2007 Jun;28(6):789-95 - PubMed
  4. Drug Metab Dispos. 2004 Jul;32(7):752-7 - PubMed
  5. Nephron. 1992;60(4):460-5 - PubMed
  6. Acta Pharmacol Sin. 2009 Sep;30(9):1245-52 - PubMed
  7. Exp Toxicol Pathol. 1997 Dec;49(5):337-41 - PubMed
  8. Life Sci. 1993;52(22):PL239-44 - PubMed
  9. Nephron. 1991;57(1):78-83 - PubMed
  10. Planta Med. 1997 Feb;63(1):22-6 - PubMed
  11. Rapid Commun Mass Spectrom. 2004;18(23):2878-82 - PubMed
  12. Life Sci. 2004 Aug 27;75(15):1801-16 - PubMed
  13. Planta Med. 2004 Feb;70(2):138-42 - PubMed
  14. Exp Toxicol Pathol. 1995 Nov;47(5):341-4 - PubMed

Publication Types